Factors affecting biological variations in debrisoquineoxidation polymorphism were investigated in a population of 3065 unrelated supposedly healthy Caucasian subjects, ages 35 to 50 years. This population, including 1526 men and 1539 women, was used to determine whether thedebrisoquine-oxidation phenotypecan be related with environmental factors such as alcohol intake, smoking habits or medication; with morphological variables; or with 22 blood constituents and some pathological states. A single dose of 10 mg of debrisoquine sulfate was administered to determine the oxidation phenotype. A metabolic ratio(debrisoquine/4-hydroxydebrisoquine) of 10.0 defined a poor metabolizer [frequency of 8.2% (SD 1.0%)] in this sample. Dose recoveries of debrisoquine excretion (mean and SD) were 8.9% (11.9%) and 45.1% (32.2%) in extensive and poor metabolizers, respectively. The mean (SD) amount of debrisoquine administered that was excreted in urine as 4-hydroxydebrisoquine was 17.4% (17.3%) in extensive metabolizers and 0.5% (0.9%) in poor metabolizers. The main factors differing significantly between poor and extensive metabolizers were mean cell volume, mean corpuscularhemoglobin concentration, albumin, and ponderal index. No other blood constituents (e.g., cholesterol, glucose) differed between poor and extensive metabolizers. The lack of corretation with most of the variables tested is of interest in clinical trials, because our findings indicate that no subgroups will be required, making selection of subjects easier. 
Factors affecting biological variations in debrisoquineoxidation polymorphism were investigated in a population of 3065 unrelated supposedly healthy Caucasian subjects, ages 35 to 50 years. This population, including 1526 men and 1539 women, was used to determine whether thedebrisoquine-oxidation phenotypecan be related with environmental factors such as alcohol intake, smoking habits or medication; with morphological variables; or with 22 blood constituents and some pathological states. A single dose of 10 mg of debrisoquine sulfate was administered to determine the oxidation phenotype. A metabolic ratio(debrisoquine/4-hydroxydebrisoquine) of 10.0 defined a poor metabolizer [frequency of 8.2% (SD 1.0%)] in this sample. Dose recoveries of debrisoquine excretion (mean and SD) were 8.9% (11.9%) and 45.1% (32.2%) in extensive and poor metabolizers, respectively. The mean (SD) amount of debrisoquine administered that was excreted in urine as 4-hydroxydebrisoquine was 17.4% (17.3%) in extensive metabolizers and 0.5% (0.9%) in poor metabolizers. The main factors differing significantly between poor and extensive metabolizers were mean cell volume, mean corpuscularhemoglobin concentration, albumin, and ponderal index. No other blood constituents (e.g., cholesterol, glucose) differed between poor and extensive metabolizers. The lack of corretation with most of the variables tested is of interest in clinical trials, because our findings indicate that no subgroups will be required, making selection of subjects easier. In 1977 in London, some subjects were discovered to be unable to transform an antthypertensive drug, debrisoquine, into its main oxidized metabolite, 4-hydroxydebrisoquine (5). These individuals, called poor metabolizers, excrete a very low quantity of the metabolite, whereas extensive metabolizers, in the same conditions of treatment, eliminate in their urine a greater quantity of the metabolite than of the parent drug (5, 6) . The clinical consequences of polymorphic oxidation depend on the characteristics of the drug in extensive hydroxylators and on the quantitative importance of the defective pathway in the overall elimination of the drug. A deficient metabolism may cause accumulation of the parent drug and thereby stronger or prolonged effects and concentration-dependent adverse reactions. In contrast, in extensive metabolizers, it is sometimes necessary to increase the administered dose to obtain therapeutic efficiency. Poor 4-hydroxylation of debrisoquine appears to involve -8% of the Caucasian pepulation, but this frequency is much lower in some other ethnic groups (7, 8) . Thus, it is impertant to know the oxidation phenotype in clinical trials.
AdditionalKeyphrases
Genetic polymorphism related to the P-45011D6 isoenzyme is the dominant cause of interindividual variation in the elimination of several drugs. If the pharmacokinetic variability is large relative to the therapeutic index of the drug, the genetic polymorphism will be clinically important, e.g., in adjusting the dose of the drug. Among 
Materials and Methods
Samples. Urine samples were collected over an 8-h period just after ingestion of the test substance.
Analytical procedures.
Debrisoquine and its main metabolite, 4-hydroxydebrisoquine, were measured in urine by a HPLC assay without extraction (9) . In the routine assay, standard curves were prepared by mixing 4 mg) of debrisoquine (molecular mass 175.2 Da), and then collect urine over the following 8 h. Phenotype was assigned by using the metabolic ratio (MR), calculated as micromoles (or milligrams) of debrisoquine per micromoles (or milligrams) of 4-hydroxydebrisoquine: 0-8 h urinary excretion of unchanged debrisoquine
Results

Analytical Variations
Within-day imprecision of measurement was about 6 .8% for 4-hydroxydebrisoquine and 2.4% for debrisoquine. The day-to-day reproducibility of the metabolic ratios was about 16.3%, with CVs of 15.0% for 4-hydroxydebrisoquine and 10.0% for debrisoquine.
Descriptive Analysis of the Population
The repartition of the population is shown in Table 1 . The frequency distribution histogram of debrisoquine metabolic ratio (expressed as logarithm) in the 3065 subjects shows two separated phenotypic populations. In this study, subjects were declared poor metabolizers when their metabolic ratio was >10.0, which corresponds to a log of 1.0 (Figure 1) . Figure 1 shows the distribution of the logarithmic metabolic ratios. This distribution is represented as two gaussian histograms: extensive and poor metabolizers. In this case, it is appropriate to use mean and SD to describe each sub-population.
Genetically Determined Changes
The repartition of the debrisoquine metabolic ratio shows extensive metabolizers, with a log metabolic ratio between -2.0 and +1.0 (n = 2815), and poor metabolizers, whose log metabolic ratio ranged from + 1.0 to +2.6 (n = 250). Dose recoveries of debrisoquine and 4-hydroxydebrisoquine found in extensive and poor metabolizers were quite different (P <0.001).
Mean dose recovery in urine as 4 Tobacco. Smoking had no effect on the mean dose recoveries of debrisoquine and 4-hydroxydebrisoquine, regardless of the subject's sex and hydroxylation status. The frequency of poor metabolizers in the smoking population was 5.6%.
Alcohol consumption. Alcohol intake had no effect on the urinary excretions of debrisoquine and 4-hydroxydebrisoquine among extensive metabolizers, regardless the volume of alcohol consumed. Two groups were compared: control group without alcohol intake and those who drink >22 g/day. The frequency of poor metabolizers in the drinking population was 7.2%.
Morphometric Parameters
The influence of body weight on debrisoquine oxidation was studied by using the ponderal index of the degree of overweight.
Excess 
Biological Comparisons between Poor and Extensive
Metabolizers
Poor and extensive metabolizers of similar weight index, alcohol consumption, and taking no medication were compared by using a logistic regression for biological and hematological constituents measured during health examination (listed in Table 5 ). We found a significant statistical difference for mean corpuscular volume, mean corpuscular hemoglobin, and albumin.
Student's t-test for matched samples gave a t-value of 3.09 for mean corpuscular volume (P <0.01), 2.92 for mean corpuscular hemoglobin (P <0.01), and 2.29 for albumin (P <0.05). Mean values of the first two were lower and the mean value of albumin was greater in poor metabolizers than in extensive metabolizers, but this last difference was no greater than the analytical variation of the method (CV 4%). Because, as is well known, several clinical laboratory analytes vary with age and sex (12), we confirmed these results by performing a stepwise logistic regression with morphological, biological, and hematological variables and some pathologies, according to age and sex, for classifying the importance of the effect of each variable.
Only three 
Discussion
Enzyme activities are usually modified in plasma by various factors, e.g., age, sex, overweight, drug intake (12). These same factors may affect debrisoquine excretion and thus modifr the metabolic ratio. Investigating a large and supposedly healthy population, we tried to evaluate the effects of some of these factors on debrisoquine 4-hydroxylation polymorphism.
The cutoff value for separating extensive and poor phenotypes was 10.0, i.e., log metabolic ratio = 1.0, which differs slightly from that reported in the literature (22). Figure 1 shows a continuity between the two phenotypes, in contrast to all other studies, which show a good partition between poor and extensive metabolizers. This result may be explained by the fact that we examined a large number of subjects (>3000). Among these, only 15 subjects had a logarithmic ratio between 1.1 and 1.2 (0.5%) and 25 subjects between 1.0 and 1.2 (0.8%). These 25 results were confirmed by a gaschromatographic method (23), so misclassification through analytical error can be eliminated. These 25 patients did not take any drug. They were assigned as poor metabolizers in this study. In the studied population, the frequency of the poor metabolizer trait was 8.2% with small confidence limits (1.0%), whereas reported limits in the literature were usually around 5.0% (Table 6 ). If we use a metabolic ratio value of 12.6(22) to determine the two phenotypes, the frequency of poor 18, 24, 25) . However, the frequency of the poor-metabolizer phenotype is known to vary with the ethnic groups (7, 26, 27) . The Steiner et al. (25) . Moreover, the lack of influence of age or sex reported in this study is also in agreement with the findings of Steiner et al. (25) .
In our study population, 1037 subjects took drugs, but other potential subjects, who used inhibitory drugs of the hydroxylation polymorphism such asquinidine, propafenone, and antihypertensive drugs, were excluded from the study. The distribution of the hydroxylation status did not differ between subjects under medication or not using drugs. Apparently the use of drugs did not interfere with phenotyping, except for antiparasitic and H2-antihistaminic drugs. Perhaps there is competition between debrisoquine and these kinds of drugs; for example, Nivaquine (chloroquine) encloses a quinoleic core (as do quinidine and quinine, which inhibit cytochromeP-45011D1), and debrisoquine contains also an isoquinoleic core. More investigations of microsomes must be undertaken to determine whether chloroquine is a slight inhibitor of P-450s. H2-antihistaminic drugs, e.g., ranitidine or cimetidine, could themselves be fixed on cytochrome P-450s and decrease the hepatic blood flow. Ranitidine, like cimetidine, probably reduces the clearance of compounds undergoing biotransformation by the cytochrome P-450s. We know that cimetidine inhibits a number of drug-metabolizing processes, and Steiner (16) showed that cimetidine inhibits the oxidative metabolism of tricyclic antidepressant desipramine in extensive but not in poor hydroxylators.
Contraceptive drugs did not modifr the distribution of the log metabolic ratio among women and the debrisoquine or 4-hydroxydebrisoquine excretions.
Previous reports show that tobacco did not influence the debrisoquine hydroxylation (25). However, our study shows that the extensive metabolizers who are smokers present a decrease in debrisoquine excretion and a slight increase in 4-hydroxydebrisoquine excretion, but these differences were not statistically significant (results not shown). The percentage of poor metabolizers was similar between smokers and nonsmokers (Table 4) .
Alcohol consumption did not change the distribution of the log metabolic ratio or the urinary excretion of both debrisoquine and 4-hydroxydebrisoquine.
The percentage of the poor hydroxylation status was 7.5% in a control population and 7.2% in the drinking population we studied.
Ponderal
index from the poor metabolizers was slightly higher than that of the extensive metabolizers. It could be explained by the difference of weight between poor and extensive subjects resulting from the regression analysis.
In comparing the two groups of metabolizers to determine whether the hydroxylator status was related to an increase or a decrease of the rate of several blood constituents, only mean corpuscular volume was significantly different, being lower in the poor metabolizer group (P <0.01).
In conclusion, we have demonstrated that debrisoquine hydroxylation is polymorphic in French subjects, with an allelic frequency of the poor metabolizer trait of 0.286. In many previous investigations of Caucasians or other ethnic groups, the frequency of poor hydroxylators varied between 0% and 30%. In this study, the cutoff for separating extensive and poor metabolizers was 10.0, which is slightly lower than for other studies but gives a narrower confidence limit. Because some drugs (e.g., ranitidine, chloroquine) can slightly affect the phenotypic expression of debrisoquine 4-hydroxylation, this last factor (drug interaction) must be taken into account forclinical trials. But it is not necessary to divide the selected population intosubgroupsaccording toage,sex, overweight, or other such factors.
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